1848 related articles for article (PubMed ID: 31373710)
1. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
2. The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review.
Carpi RZ; Barbalho SM; Sloan KP; Laurindo LF; Gonzaga HF; Grippa PC; Zutin TLM; Girio RJS; Repetti CSF; Detregiachi CRP; Bueno PCS; Mazuqueli Pereira ESB; Goulart RA; Haber JFDS
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955942
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.
Ebrahimzadeh Leylabadlo H; Ghotaslou R; Samadi Kafil H; Feizabadi MM; Moaddab SY; Farajnia S; Sheykhsaran E; Sanaie S; Shanehbandi D; Bannazadeh Baghi H
Eur J Clin Microbiol Infect Dis; 2020 Apr; 39(4):613-627. PubMed ID: 31828683
[TBL] [Abstract][Full Text] [Related]
5. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
Cho MS; Kim SY; Suk KT; Kim BY
J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
[TBL] [Abstract][Full Text] [Related]
6. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
[TBL] [Abstract][Full Text] [Related]
7. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view.
Chen HT; Huang HL; Li YQ; Xu HM; Zhou YJ
World J Gastroenterol; 2020 Apr; 26(16):1901-1911. PubMed ID: 32390701
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory effects of probiotics and synbiotics on patients with non-alcoholic fatty liver disease: An umbrella study on meta-analyses.
Mahapatro A; Bawna F; Kumar V; Daryagasht AA; Gupta S; Raghuma N; Moghdam SS; Kolla A; Mahapatra SS; Sattari N; Amini-Salehi E; Nayak SS
Clin Nutr ESPEN; 2023 Oct; 57():475-486. PubMed ID: 37739694
[TBL] [Abstract][Full Text] [Related]
10. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease.
Hartmann P; Schnabl B
Semin Liver Dis; 2021 Jan; 41(1):87-102. PubMed ID: 33957682
[TBL] [Abstract][Full Text] [Related]
11. Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT).
Nobili V; Mosca A; Alterio T; Cardile S; Putignani L
Adv Exp Med Biol; 2019; 1125():85-100. PubMed ID: 30578461
[TBL] [Abstract][Full Text] [Related]
12. Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Rong L; Ch'ng D; Jia P; Tsoi KKF; Wong SH; Sung JJY
J Gastroenterol Hepatol; 2023 Oct; 38(10):1682-1694. PubMed ID: 37409560
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
Han R; Ma J; Li H
Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
[TBL] [Abstract][Full Text] [Related]
14. Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease.
Kaufmann B; Seyfried N; Hartmann D; Hartmann P
Am J Physiol Gastrointest Liver Physiol; 2023 Jul; 325(1):G42-G61. PubMed ID: 37129252
[TBL] [Abstract][Full Text] [Related]
15. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
16. The promising role of probiotics/prebiotics/synbiotics in energy metabolism biomarkers in patients with NAFLD: A systematic review and meta-analysis.
Li S; Liu J; Wang Z; Duan F; Jia Z; Chen X; Li S
Front Public Health; 2022; 10():862266. PubMed ID: 35958869
[TBL] [Abstract][Full Text] [Related]
17. Probiotics and synbiotics may improve liver aminotransferases levels in non-alcoholic fatty liver disease patients.
Buss C; Valle-Tovo C; Miozzo S; Alves de Mattos A
Ann Hepatol; 2014; 13(5):482-8. PubMed ID: 25152979
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD.
Gupta M; Krishan P; Kaur A; Arora S; Trehanpati N; Singh TG; Bedi O
Inflamm Res; 2021 Jul; 70(7):765-776. PubMed ID: 34212214
[TBL] [Abstract][Full Text] [Related]
19. Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies.
Jayachandran M; Qu S
Rev Endocr Metab Disord; 2023 Dec; 24(6):1189-1204. PubMed ID: 37840104
[TBL] [Abstract][Full Text] [Related]
20. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics.
Nagashimada M; Honda M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]